11/15/2026

Janusmed amning

Janusmed amning – Cimzia

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Certolizumabpegol

Certolizumabpegol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890-1896.

  2. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.

  3. Prieto-Peña D, Calderón-Goercke M, Adán A, Chamorro-López L, Maíz-Alonso O, De Dios-Jiménez Aberásturi JR et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol. 2021;39(1):105-114.

  4. Lambiase S, Pensa C, Shumak RG, Bianchi L, Dattola A. Certolizumab pegol in pregnant and breastfeeding psoriatic patients. Ital J Dermatol Venerol. 2022;1(1):1.

  5. Membrive-Jiménez C, Sánchez-Piedra C, Martínez-González O, García-González J, Expósito-Pérez L, Bohórquez-Heras C et al. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry. Reumatol Clin (Engl Ed). 2023 Nov;19(9):500-506.

  6. Acar B, Aktas B, Ayla AY, Eren H, Alkan A, Ugurlu S. Pregnancy and Lactation Outcomes of Women With Rheumatic Diseases Treated With Certolizumab Pegol: Real-World Experience From a Tertiary Center. Int J Rheum Dis. 2026;29(6):e70741.

  1. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890-1896.
  2. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.
  3. Prieto-Peña D, Calderón-Goercke M, Adán A, Chamorro-López L, Maíz-Alonso O, De Dios-Jiménez Aberásturi JR et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol. 2021;39(1):105-114.
  4. Lambiase S, Pensa C, Shumak RG, Bianchi L, Dattola A. Certolizumab pegol in pregnant and breastfeeding psoriatic patients. Ital J Dermatol Venerol. 2022;1(1):1.
  5. Membrive-Jiménez C, Sánchez-Piedra C, Martínez-González O, García-González J, Expósito-Pérez L, Bohórquez-Heras C et al. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry. Reumatol Clin (Engl Ed). 2023 Nov;19(9):500-506.
  6. Acar B, Aktas B, Ayla AY, Eren H, Alkan A, Ugurlu S. Pregnancy and Lactation Outcomes of Women With Rheumatic Diseases Treated With Certolizumab Pegol: Real-World Experience From a Tertiary Center. Int J Rheum Dis. 2026;29(6):e70741.

Innehållet senast uppdaterat 11/3/2026